SMMT logo

SMMT Summit Therapeutics Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$9.95
-0.62 (-5.87%)

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an ora…

Market Cap: $7.96Bwww.smmttx.com

Price

No data yet.

Social Signal Score

40
5d
50
1 mentions
—
30d
31
16 mentions
—
60d
37
38 mentions
—
90d
43
59 mentions
—
news: 28 · rss: 27 · marketaux: 4

Analyst Ratings

23 analysts
Buyconsensus
Strong Buy 0Buy 15Hold 8Sell 0Strong Sell 0
Avg price target$33.13+233.0%
Low $20Median $35.5High $41
Current Consensus

Revenue

$0.00-100.00%
$0.00$16.62M$33.24M$49.86M
Jan 2017Sep 2026

Analyst Estimates

FY2025
$-1.11
$-1.47–$-0.50
7 analysts
FY2026
$-1.07
$-1.27–$-0.98
8 analysts
FY2027
$-1.02
$-1.22–$-0.90
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Robert W. Duggan
Sector
Healthcare
Industry
Biotechnology
Employees
265
Beta
-1.24
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
19.59
www.smmttx.com